Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A “Real-Life” Observational Study in the First Year of Treatment

Journal of Clinical Medicine

卷:11

Marco Corbò¹  Giuseppe Alberto Di Bella¹  Camilla Spanu¹  Davide Paolo Porru¹  Claudio Montuori¹  Daniele Penazzi¹  Simone Lo Verde¹  Matteo Bonini²  Eleonora Nucera³  Stefano Settimi⁴  Jacopo Galli⁴  Giulio Cesare Passali⁴  Eugenio De Corso⁴  Gaetano Paludetti⁴ 

[1] Department of Head and Neck and Sensory Organs, Catholic University of the Sacred Hearth, 00168 Rome, Italy;

[2] Department of Internal Medicine and Geriatrics, Catholic University of the Sacred Hearth, 00168 Rome, Italy;

[3] Unit of Allergology, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, Italy;

[4] Unit of Otorhinolaryngology—Head and Neck Surgery, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, Italy;

关键词: chronic rhinosinusitis with nasal polyps;    type-2 inflammation;    asthma;    biologics;    dupilumab;    real life;   

DOI  :  10.3390/jcm11102684

来源: DOAJ

【 摘 要 】

The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), with or without asthma as add-on therapy with intra-nasal corticosteroids in a real-life setting over the first year of treatment. Our data demonstrated that subcutaneous 300 mg dupilumab administered at home via a pre-filled auto-injector every two weeks, based on indications set by the Italian Medicines Agency, was rapidly effective in reducing the size of polyps, decreasing symptoms of disease, improving quality of life, and recovering olfaction. Significant improvement was observed after only 15 days of treatment, and it progressively increased at 6 and 12 months. Dupilumab was also effective in reducing the local nasal eosinophilic infiltrate, in decreasing the need for surgery and/or oral corticosteroids, and in improving control of associated comorbidities such as chronic eosinophilic otitis media and bronchial asthma. After 12 months of treatment, 96.5% of patients had a moderate/excellent response. From our data, it was evident that there was a group of patients that showed a very early response within one month of therapy, another group with early response within six months from baseline, and a last group that improved later within 12 months. The results of this study support the use of dupilumab as an effective option in the current standard of care for patients affected by severe uncontrolled CRSwNP.

【 授权许可】

Unknown